Our scientific publications Filter by Programme All RXC004 RXC007 GI-targeted ROCK RXC006 RXC005 Programme Key External Link PDF ELRIG 2020 Poster – Validation of immune cell analysis in whole blood by flow cytometry for clinical biomarker investigation RXC004 AACR 2019 – Efficacy of the Wnt/Beta-Catenin pathway inhibitor RXC004 in genetically-defined models of cancer RXC004 AACR 2019 – Wnt/b-Catenin pathway inhibitor RXC004 enhances the immunity of pre-clinical models of cancer RXC004 ERS 2019 Poster – Pre-clinical data using candidate compound RXC006 demonstrates that porcupine is a novel and promising target for the treatment of IPF RXC006 3rd NASH Summit London 2019 Poster – ROCK2 selective inhibitors for the treatment of fibrosis RXC007 Paris NASH Meeting 2019 Poster – Selective ROCK2 inhibitors for the treatment of fibrosis RXC007 Integrated Pathways of Disease in NASH and NAFLD 2019 – ROCK2 inhibitors for the treatment of fibrosis RXC007 NCRI 2018 – Efficacy of the Porcupine inhibitor RXC004 in genetically-defined tumour types RXC004 Porcupine inhibitor RXC004 enhances immune response in pre-clinical models of cancer RXC004 AFDD 2108 Poster – Wnt Pathway Suppression and Fibrosis RXC006 ASN 2018 – ROCK2 inhibitors for the treatment of chronic kidney disease RXC007 ECCO 2018 Poster – Redx GI restricted ROCK inhibitors show potential to treat fibrosis and stenosis associated with inflammatory bowel disease GI-targeted ROCK Keystone Symposia 2017 Poster – Porcupine inhibitors demonstrate suitability for use as novel anti-fibrotic therapeutics RXC006 ESMO 2017 – Identification of an RNF43 mutated gastric cancer patient population with potential sensitivity to porcupine inhibitor RXC004 and development of a complimentary ctDNA liquid biopsy assay for patient screening. RXC004 iwCLL 2017 – RXC005, a Potent and Selective, Reversible BTK Inhibitor Targeting both Wild-type and Mutant C481S BTK with Potent Efficacy in ABC-DLBCL Xenograft Mouse Models RXC005 EORTC 2016 – Novel Porcupine inhibitor RXC004: Potent efficacy in animal models of cancer through direct tumour targeting and immunomodulatory mechanisms RXC004 ASH 2016 – RXC005 (REDX08608), a Novel, Potent and Selective, Reversible BTK Inhibitor with Efficacy and Equivalent Potency Against Wild-Type and Mutant C481S BTK (poster) RXC005 Guisot et al. 2016 – RXC005 (REDX08608), a Novel, Potent and Selective, Reversible BTK Inhibitor with Efficacy and Equivalent Potency Against Wild-Type and Mutant C481S BTK RXC005 About us Presentations, analyst reports, documents & videos News & events
